Claims for Patent: 9,157,907

Summary for Patent: 9,157,907

Title:	Panels of immortalized mammalian cells and their use
Abstract:	Panels of mammalian cell samples, kits and methods of use thereof. The panels comprise samples or sets of samples of immortalized primary cells, obtained from different tissues and organs of healthy and/or diseased donors. The cell panels are useful in assays for testing effects of drug candidates, e.g. for activity and toxicity.
Inventor(s):	Grillari; Johannes (Bisamberg, AT), Grillari; Regina (Bisamberg, AT), Kanzler; Otto (Boeheimkirchen, AT)
Assignee:	Universitat fur Bodenkultur Wien (Vienna, AT)
Application Number:	13/695,423
Patent Claims:	1. A method for preparing a panel of mammalian cells for testing efficacy or toxicity by means of a bioassay, said method comprising the steps of: i) providing immortalized primary cells from tissues and/or organs that are relevant for testing efficacy or toxicity of an agent, wherein said tissues and/or organs are from one or more healthy and/or diseased donors, and wherein the cells are selected from the group consisting of fibroblasts, epithelial cells, myoblasts, endothelial cells, cardiomyocytes, blood cells, keratinocytes, osteoblasts, urothelial cells, fetal liver cells, Schwann cells, neural progenitor cells, Sertoli cells, and human exfoliated proximal tubular epithelial cells; ii) selecting, from the cells obtained in step i), cells that are, with respect to at least one predetermined morphological or functional property that is essential for the read-out of said bioassay, identical to corresponding primary cells, wherein the property is selected from the group consisting of expression of a target or marker molecule, phenotypic differentiation potential, neoangiogenic potential, uptake capacity for certain molecules, apoptotic capacity, capacity for formation of tight junctions and/or domes, expression of aminopeptidase N, cAMP induction by parathyroid hormone, sodium-dependent phosphate uptake, transport of molecules mediated by megalin and/or cubilin, and response to inflammatory signals; iii) providing cell samples comprising the cells selected in step ii), wherein the cell samples are derived from at least five donors or are from at least two different organs and/or tissues of the same donor; iv) providing one or more cell samples selected from the group consisting of kidney cells, liver cells, blood cells, endothelial cells, and skin cells; v) combining different cell samples of step iii) to form sets of cell samples; vi) combining sets of cell samples of step v) with cell samples of step iv) to form a panel of cell samples; and vii) testing the efficacy or toxicity of the agent with the panel of cell samples of step vi). 2. The method of claim 1, wherein said bioassay is a cytotoxicity assay and wherein the cells in the samples according to step iv) are one or more cells samples selected from the group consisting of kidney cells, liver cells, blood cells, endothelial cells, and skin cells. 3. The method of claim 1, wherein step iii) comprises providing cell samples comprising the cells selected in step ii), and wherein the cell samples are derived from at least five donors. 4. The method of claim 1, wherein step v) comprises combining cell samples from at least five donors to form sets of cell samples.

Details for Patent 9,157,907

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2030-04-30